Table of Contents      
Intro and Overview
     Introduction
     Business Overview
Trends and Forces
      Key Trends and Forces
Competition


Competition Among Major Drug Manufacturers

Johnson & Johnson's major competitors include Pfizer, Merck, and Novartis. In the medical devices space, its competitors include Medtronic (MDT) and Boston Scientific (BSX). In the orthapedic implants segment, it competes with Zimmer Holdings (ZMH) and Stryker (SYK).

Competition in the health care industry lies mostly in specific markets. For example, a new diabetes drug is not going to have any effect on an existing cholesterol drug, no matter how successful it is. This concept is especially true in the case of Johnson & Johnson, which due to its diverse product offerings in multiple segments of the industry, simultaneously competes in hundreds of distinct markets. With this in mind, success in this competitive environment requires substantial investments in research and sales.

The table below displays competitive operating metrics for competitors within the pharmaceutical industry. Note that the total revenue for Merck and Pfizer was influenced by revenue inherited from their acquisitions of Schering-Plough and Wyeth, respectively. In addition, net income for Merck was bolstered by $3.2 billion from the sale of its animal division [1], while Bristol-Meyers Squibb's net income saw a one-time $7.2 billion increase from the sale of its nutrition division.[2]


Pharmaceutical and Biotech Industry — Competitive Operating Metrics (2009)

 

Johnson & Johnson (JNJ)

Pfizer (PFE)

Novartis (NVS)

Abbott Laboratories (ABT)

Merck (MRK)

Bristol-Meyers Squibb (BMY)

Eli Lilly (LLY)

Amgen (AMGN)

Gilead (GILD)

AstraZeneca (AZN)

Roche (RHHBY)

Revenue (in billions of USD)

Total Revenue

$61.9

$50.0

$44.3

$30.8

$27.4

$18.8

$21.8

$14.6

$7.0

$32.8

$49.1

Gross Profit

$43.5

$41.1

$32.1

$17.6

$18.4

$13.7

$17.6

$12.6

$5.4

$27.2

$34.4

Revenue Growth from 2008

-2.9%

3.5%

4.0%

4.2%

15.0%

6.2%

7.2%

-2.4%

31.4%

3.8%

7.5%

Income

Net Income

$12.3

$8.6

$8.4

$5.8

$12.9

$10.6

$4.3

$4.6

$2.6

$7.5

$7.8

Net Profit Margin

19.8%

17.3%

19.0%

18.7%

47.0%

56.4%

19.8

31.5%

37.6%

22.9%

15.9%

Operating Income

$15.8

$10.8

$10.0

$6.2

$15.3

$5.6

$5.4

$5.5

$3.5

-$11.5

$11.9

Diluted EPS Growth from 2008

-3.7%

2.5%

3.7%

21.8%

55.6%

20.7%

NA

19.6%

36.9%

23.6%

-11.8%

Other

R&D Spending

$7.0

$7.8

$7.5

$2.7

$5.9

$5.1

$4.3

$2.9

$0.9

$4.4

$9.9

Intro and Overview | Trends and Forces | Competition

References

  1. Merck Announces Fourth-Quarter and Full-Year 2009 Financial Results
  2. Bristol beats forecast, helped by lower taxes
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki